Trial Profile

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Antithymocyte globulin
Indications Acute myeloid leukaemia; Advanced breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cancer
Focus Therapeutic Use

Most Recent Events

30 Apr 2019 Status changed from active, no longer recruiting to discontinued.
05 Jul 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
05 Jul 2018 Planned primary completion date changed from 15 Jun 2018 to 15 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com